Mythies Kumar Sellamuthu

Publications (3) View all

• Article: RP-HPLC-DAD for simultaneous estimation of mahanine and mahanimbine in Murraya koenigii.

  Subrata Pandit, Mythies Kumar, S Ponnusankar, B C Pal, Pulok K Mukherjee
  [show abstract] [hide abstract]
  ABSTRACT: Murraya koenigii leaves (Rutaceae) are widely used as food condiments in various food preparations in India. They possess a wide range of biological activities including antioxidant, antibacterial, anticancer, hypoglycemic and hypolipidemic activity. A rapid reverse-phase high-performance liquid chromatography (RP-HPLC) method has been developed for quantitative estimation of mahanine and mahanimbine, two major bioactive alkaloids in this plant. The amounts of mahanine and mahanimbine were detected as 9.56 ± 1.04 and 4.32 ± 0.81% w/w in the extract, with the retention times of 6.26 ± 0.66 and 10.40 ± 0.95 minutes. The limits of detection and quantification were estimated to be 29.30 and 81.12 µg/mL and 1.67 and 6.31 µg/mL, respectively. This specific and precise validated method can be useful for the routine analysis and quantitative determination of mahanine and mahanimbine in this therapeutically potent medicinal plant.
  Biomedical Chromatography 03/2011; 25(9):959-62. · 1.97 Impact Factor
• Article: Simultaneous estimation of hydroxychavicol and chlorogenic acid from Piper betel L. through RP-HPLC.

  Niladri Maity, Neelesh K Nema, Mythies K Sellamuthu, Birendra K Sarkar, Pulok K Mukherjee
  [show abstract] [hide abstract]
  ABSTRACT: A RP-HPLC method was developed (λ (max) = 280) to quantify hydroxychavicol and chlorogenic acid in Piper betel Linn. The method was validated for linearity, limit of detection (LOD = 3:1σ/S), limit of quantification (LOQ = 10:1σ/S), precision, accuracy and ruggedness. The response was linear with good correlation between concentration and mean peak area through a coefficient of determinants (r (2)) of 0.9940, y = 1.98e + 004x + 5.19e + 004 and 0.9945, y = 2.76e + 004x + 1.40e + 005 with LOD 1.6 µg mL(-1), 1.0 µg mL(-1) and LOQ 5.0 µg mL(-1) and 3.0 µg mL(-1), respectively, for hydroxychavicol (28.56% w/w) and chlorogenic acid (0.40% w/w). The %RSD of precision and recovery of hydroxychavicol and chlorogenic acid were <2.0%. The proposed method was simple, accurate, specific, precise and reproducible.
  Natural product research 09/2011; 26(20):1939-41. · 1.01 Impact Factor
• Source

  Available from: Giriraj T Kulkarni

  Article: FORMULATION AND IN VITRO EVALUATION OF ARAUCARIA BIDWILLI GUM-BASED SUSTAIN RELEASE MATRIX TABLETS OF DICLOFENAE SODIUM

  J. ASHOK KUMAR, M.RAJESH, S.MYTHIESH KUMAR, T. GIRIRAJ KULKARNI, V. GOPAL
  [show abstract] [hide abstract]
  ABSTRACT: A gel forming Polysaccharide gum obtained form the bark of Araucaria bidwilli was employed as a matrix sustained release tablet formulation of Diclofenac sodium (a non steroidal anti inflammatory agent). The effect of Araucaria bidwilli gum (Natural) and Synthetic polymer Hydroxypropyl methyl cellulose (HPMC K4 M) on the release of Diclofenac sodium was studied. The FT-IR spectroscopic studies of drug, gum and mixture indicated no chemical interaction. Six formulations were prepared by wet granulation method containing Araucaria bidwilli gum powder concentration 10% 20% & 30% w\w and 10% 20% &30% w\w of HPMC K4 M with sufficient volume of granulating agent Polyvinyl pyrrolene (PVP K 30), Avicel pH101 as diluents, Magnesium stearate and Aerosil is used lubricant and glidant respectively.This study was carried out to find out the difference between synthetic and natural gum and whether synthetic gum can be replaced by natural gums. Physical and technological studies of granules and tablets were compliance with Pharmacopoial standards.The drug release increased with Araucaria bidwilli gum when compared to synthetics polymer concentration .The value of release exponent were found to be almost straight line and regression coefficient value between 0.938 and 0.998.This implies that the release mechanism is diffusion. Formulation F3 ( contained 30% w\w Araucaria bidwilli gum) met the desired requirements for a sustained release dosage form.
  Journal of Pharmaceutical Research and health Care 01/2011;